The molecular tumor burden index as a response evaluation criterion in breast cancer
Open Access
- 7 July 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Signal Transduction and Targeted Therapy
- Vol. 6 (1), 1-8
- https://doi.org/10.1038/s41392-021-00662-9
Abstract
Circulating tumor DNA (ctDNA) is a potential biomarker of prognosis and therapeutic response. We conducted this study to explore the role of the molecular tumor burden index (mTBI) in ctDNA as a therapeutic response and prognostic biomarker in a larger cohort prospective phase III randomized multicenter study. We collected 291 plasma samples from 125 metastatic breast cancer patients from the CAMELLIA study (NCT01917279). Target-capture deep sequencing of 1021 genes was performed to detect somatic variants in ctDNA from the plasma samples. The pretreatment mTBI value was correlated with tumor burden (P = 0.025). Patients with high-level pretreatment mTBI had shorter overall survival than patients with low-level pretreatment mTBI, and the median overall survival was 40.9 months and 68.4 months, respectively (P = 0.011). Patients with mTBI decrease to less than 0.02% at the first tumor evaluation had longer progression-free survival and overall survival (P < 0.001 and P = 0.007, respectively). The mTBI has good sensitivity to identify complete response/partial response and progressive disease based on computed tomography scans (88.5% and 87.5%, respectively). The patients classified as molecular responders had longer progression-free survival and overall survival than the nonmolecular responders in the overall cohort (P < 0.001 and P = 0.036, respectively), as well as in the cohort in which computed tomography scans were defined as representing stable disease (P = 0.027 and P = 0.015, respectively). The mTBI in ctDNA detected in liquid biopsies is a potential biomarker of therapeutic response and prognosis in patients with metastatic breast cancer.Keywords
Funding Information
- National Natural Science Foundation of China (81874122)
- CAMS Initiative for Innovative Medicine’
This publication has 31 references indexed in Scilit:
- RECIST — learning from the past to build the futureNature Reviews Clinical Oncology, 2016
- ctDNA dynamics: a novel indicator to track resistance in metastatic breast cancer treated with anti-HER2 therapyOncotarget, 2016
- Genomic Alterations in Liquid Biopsies from Patients with Bladder CancerEuropean Urology, 2016
- Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice GuidelineJournal of Clinical Oncology, 2015
- Short report: Monitoring ESR1 mutations by circulating tumor DNA in aromatase inhibitor resistant metastatic breast cancerInternational Journal of Cancer, 2015
- Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancerAnnals of Oncology, 2014
- Analysis of Circulating Tumor DNA to Monitor Metastatic Breast CancerThe New England Journal of Medicine, 2013
- Metastatic Breast Cancer, Version 1.2012Journal of the National Comprehensive Cancer Network, 2012
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Circulating mutant DNA to assess tumor dynamicsNature Medicine, 2008